GLP-1 receptor agonist medications, commonly used for weight loss and diabetes, appear to improve liver health in people living with HIV by reducing markers of liver scarring and fibrosis. New research presented at a major HIV conference found that semaglutide was associated with reduced liver fibrosis scores, with the greatest improvements seen in people who had the most advanced liver damage. What Are GLP-1 Medications and How Do They Work? GLP-1 receptor agonists, including semaglutide (sold as Ozempic or Wegovy) and tirzepatide (Mounjaro or Zepbound), are medications that mimic a natural hormone in your body. These drugs suppress appetite, regulate blood sugar and insulin levels, and slow stomach emptying. Originally developed to treat type 2 diabetes, they're now widely prescribed for weight management. Researchers have also been studying them for fatty liver disease, addiction, and other conditions. For people with HIV, weight gain and metabolic problems are growing health concerns as they age. This makes GLP-1 medications particularly relevant, since they address multiple health issues at once. How Did Researchers Study Liver Health in This Population? A team from the University of Washington analyzed data from 1,850 people with HIV who started semaglutide for either diabetes or weight loss. Researchers measured liver fibrosis using a FIB-4 score, which combines age, platelet count, and two liver enzyme levels called ALT and AST. About three-quarters of participants were men with a median age of 52 years. Most had an undetectable HIV viral load, meaning their HIV was well-controlled with medication. At the start of the study, the majority of participants had minimal liver damage. Specifically, 74% had absent to mild fibrosis, 23% had moderate fibrosis, and 3% had advanced fibrosis. Fibrosis is liver scarring that develops when the liver becomes inflamed or fatty over time. What Did the Study Find About Liver Improvement? Semaglutide was associated with reduced FIB-4 fibrosis scores in participants with moderate to advanced liver stiffness. The improvement was most dramatic in people who started with the worst fibrosis, suggesting the medication may be especially helpful for those with more advanced liver damage. "Our findings, together with earlier studies, suggest semaglutide could play a role in managing MASLD and liver fibrosis in people with HIV, especially as they age and experience the longer-term impacts of cardiometabolic disease," the researchers concluded. Jimmy Ma, MD, University of Washington MASLD stands for metabolic dysfunction-associated steatotic liver disease, which is the buildup of fat in the liver. When this condition becomes severe and includes inflammation, it's called MASH (metabolic dysfunction-associated steatohepatitis). Over time, fat accumulation can lead to inflammation, fibrosis, cirrhosis, and even liver cancer. Why Is This Important for People With HIV? People living with HIV face unique metabolic challenges. As they age and their antiretroviral medications work to control the virus, they often develop weight gain, high blood pressure, and fatty liver disease. These conditions increase their risk of heart disease, kidney disease, and liver damage. The FDA recently approved Wegovy (a brand of semaglutide) specifically for treating MASH in people with moderate to advanced fibrosis, based on studies in HIV-negative populations. The new findings suggest these medications could offer similar benefits to people with HIV, addressing multiple health problems simultaneously. How to Assess Your Liver Health if You Have HIV - Know Your Liver Enzyme Levels: Ask your doctor for your ALT and AST levels, which are liver enzymes that appear in blood tests. Elevated levels can signal liver inflammation or damage. - Understand Your Fibrosis Risk: If you have metabolic risk factors like obesity, diabetes, or metabolic syndrome, discuss your liver fibrosis risk with your healthcare provider. They can calculate a FIB-4 score using your age, platelet count, and liver enzyme levels. - Monitor Weight and Metabolic Health: Regular weight checks, blood pressure monitoring, and blood sugar testing help catch metabolic problems early before they damage your liver. - Discuss GLP-1 Options With Your Doctor: If you have weight gain, diabetes, or signs of fatty liver disease, ask whether a GLP-1 medication might be appropriate for you, especially if you also have moderate to advanced liver fibrosis. What Other Health Benefits Did People Experience? Beyond liver improvements, people with HIV taking GLP-1 medications experienced several other health gains. In one analysis of 61 people with HIV taking tirzepatide, participants lost an average of 14% of their baseline body weight at 12 months. They also saw significant reductions in hemoglobin A1C (a measure of blood sugar control), lower blood pressure, improved HDL cholesterol (the "good" cholesterol), and lower 10-year cardiovascular disease risk scores. In another study of 204 people with HIV who smoked and started semaglutide, smoking fell by an average of 2.7 cigarettes per day, representing a 26% decrease. This additional benefit to overall health could reduce the risk of lung disease and other smoking-related conditions. Are There Any Concerns About These Medications? While the research is encouraging, some important questions remain. Early reports raised concerns about whether GLP-1 agonists might increase suicide risk, but extensive investigations by the Food and Drug Administration found no such link. In fact, some studies have shown a reduced risk. One study of 354 people with HIV starting semaglutide found that the drug was not associated with worsening depressive symptoms, regardless of whether participants had absent, mild, moderate, or severe depression at baseline. However, side effects and cost remain real barriers. In one analysis of 61 people taking tirzepatide, more than a quarter (26%) stopped taking the medication before completing one year, mostly due to either side effects or insurance issues. What's the Bottom Line? For people with HIV managing weight gain, diabetes, or fatty liver disease, GLP-1 medications like semaglutide appear to offer meaningful benefits beyond weight loss. The new research suggests they may help reduce liver fibrosis and improve markers of liver health, particularly in people with moderate to advanced damage. They also help control blood sugar, lower cardiovascular risk, and may even reduce smoking. However, access and affordability remain significant challenges, and more long-term research is needed to fully understand how these medications affect people with HIV over many years. If you're living with HIV and struggling with weight, metabolic health, or liver concerns, talk with your healthcare provider about whether a GLP-1 medication might be right for you.
